Founder of Cabbacis, Joe is the inventor on the company’s patents and leads the strategic direction of Cabbacis. He is also the founder, and was the first CEO, of 22nd Century Group, Inc. (Nasdaq: XXII) and led the process of 22nd Century becoming publicly traded in 2011. Under his leadership, the company up-listed to the New York Stock Exchange in 2013 and achieved a market capitalization of $373 million in 2014. Joe rang the Closing Bell at the New York Stock Exchange on October 16, 2014. He left 22nd Century as CEO later in 2014 and as a director in 2015. Joe’s previous company funded the R&D project of reducing nicotine in tobacco by genetic engineering that resulted in the lowest-nicotine-content tobacco variety ever commercialized. A plant variety protection (PVP) certificate was granted from the USDA for this tobacco variety, and the technology, variety rights, and related patent rights were spun out by Joe to a newly formed company, 22nd Century Limited. He has more than 25 years’ experience in all aspects of the tobacco industry, including product development and marketing, and has more than 10 years’ experience in both plant biotechnology and cannabis. He holds an MBA from the University at Buffalo.
Mike has more than 30 years’ experience in all aspects of plant biotechnology, ranging from molecular genetics to development of novel consumer products. He led R&D efforts at 22nd Century Group for 11 years, during which he played a major role in the development and production of Nicotine Research Cigarettes with different nicotine contents for the National Institute on Drug Abuse (NIDA). The Nicotine Research Cigarette series included cigarettes with nicotine concentrations ranging from higher than average to less than 5% of typical commercial cigarettes. Data from studies using these cigarettes, much of it funded by the National Institutes of Health and the Center for Tobacco Products of the Food and Drug Administration, provided the foundation for the authorization for sale of a very low nicotine cigarette brand as a Modified Risk Tobacco Product (MRTP) in the United States.
Mike’s other professional experience includes serving as Director of Biotechnology Development at Fundación Chile, Senior Project Director at InterLink Biotechnologies LLC, Principal Scientist, Cell Biology at EniChem Americas Inc., Visiting Research Fellow at the Institute for Molecular and Cellular Biology, Osaka University, Postdoctoral Associate in the Section of Plant Biology, Cornell University, and Postdoctoral Associate at the Center for Agricultural Molecular Biology, Rutgers University. Dr. Moynihan holds an ScB in Biology from Brown University and an MA and PhD in Biology from Harvard University.
Entrepreneurial CPA, business coach, and strategist whose “highest and best” use is managing businesses. Jack has over 30 years’ experience establishing, managing, restructuring, and selling privately held businesses. Extensive experience as a business leader in the health care, real estate, professional services, mortgage banking, distribution, and logistics industries. Founded U.S. Appraisal and serving as CEO, launched this regional real estate valuation services company into a national mortgage-industry leader. Led acquisition team in acquiring a large regional distribution company and completely redeveloped its infrastructure over a three-year period. Jack is committed to operational fundamentals and controls, with Big Four auditing experience at Deloitte. He holds a BS from Niagara University and is a Certified Public Accountant, licensed by the New York State Education Department.
Roger is currently a North Carolina State University, College of Agriculture & Life Sciences Research, Board Member and a Tobacco Product Development & Scientific Consultant. From 2017 to 2022, he held various positions at ITG Brands LLC, the third-largest American tobacco manufacturing company in the United States and an independent subsidiary of multinational Imperial Brands Plc, including his last position of Director of Product Development & Science. He was a Product Development and Agronomy Consultant from 2008 to 2016. From 2002 to 2008, Roger held the positions of Vice President of Product Development at RJ Reynolds Tobacco Company and Director, Product Development at Brown & Williamson Tobacco Corporation (in 2004, RJ Reynolds merged with Brown & Williamson to form a new publicly-traded company, Reynolds American). He holds an M.S and B.S. in Agronomy and Crop Science from North Carolina State University.
Paul has served as a CPA for 30 years, including roles with two Big 4 firms, as well as a sole practitioner. He is currently Director of a mid-sized, full-service CPA firm in Western New York, Arcara Lenda Eusanio & Stacey CPAs. His practice focuses on tax planning, compliance and business advisory services, including transaction support, strategic and organizational planning. He is also a co-founder, principal and investor in other businesses, including two growing retail businesses. Paul has also served as part of a senior leadership team that founded and developed a rapid growth technology company, Integrated Delivery Technologies, Inc/Cartel Network, operating a national electronic banking/transaction processing network. The company was sold to Fifth Third Bank and merged into its wholly owned subsidiary, Fifth Third Processing Solutions. He most recently also served as a Director for Buffalo Hearing & Speech from 2019 to 2023.
Paul has also served as a Director for the Boys & Girls Clubs of the Northtowns, a non-profit organization serving over 400 Western New York youths at eight facilities throughout the area from 2006 to 2012.